Pentoxifylline inhibits tumor necrosis factor-alpha induced synthesis of complement component C3 in human endothelial cells

Eric Brian Hoie, Timothy R McGuire, Patricia Mary Leuschen, Terrence Leo Zach

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Vascular endothelium is a major target for the inflammatory damage that occurs with multiple organ dysfunction associated with sepsis and other trauma. The growing appreciation of endothelium as a target of inflammation has obscured the importance of these cells as a source of inflammatory mediators. In the following study we evaluated the ability of tumor necrosis factor-alpha (TNF) to induce the synthesis of complement component C3 in human umbilical vein endothelial cells (HUVEC) and whether pentoxifylline (PTX) could reduce C3 expression. Confluent monolayers of HUVEC were treated with increasing concentrations of TNF with and without two concentrations of PTX. Concentrations of C3 were determined every 48 h for 144 h in cellular supernatants and C3 mRNA was amplified using RT-PCR. TNF increased C3 release from HUVEC in a concentration dependent manner. PTX added at the same time as TNF significantly reduced C3 release at the 96 h time point. Consistent with data on C3 release PTX inhibited the increased C3 mRNA expression associated with TNF treatment. TNF increases C3 synthesis and release from endothelial cells which were inhibited by clinical concentrations of PTX. This data further supports the potential benefit of PTX in multiple organ dysfunction and other inflammatory processes involving the endothelium by inhibiting one of the major mediators of vascular damage.

Original languageEnglish (US)
Pages (from-to)1670-1673
Number of pages4
JournalBiological and Pharmaceutical Bulletin
Volume27
Issue number10
DOIs
StatePublished - Oct 1 2004

Fingerprint

Pentoxifylline
Complement C3
Endothelial Cells
Tumor Necrosis Factor-alpha
Human Umbilical Vein Endothelial Cells
Endothelium
Messenger RNA
Vascular Endothelium
Blood Vessels
Sepsis
Inflammation
Polymerase Chain Reaction
Wounds and Injuries

Keywords

  • C3
  • Complement
  • Human umbilical vein endothelial cell (HUVEC)
  • Pentoxifylline
  • Tumor necrosis factor (TNF)-α

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Pentoxifylline inhibits tumor necrosis factor-alpha induced synthesis of complement component C3 in human endothelial cells. / Hoie, Eric Brian; McGuire, Timothy R; Leuschen, Patricia Mary; Zach, Terrence Leo.

In: Biological and Pharmaceutical Bulletin, Vol. 27, No. 10, 01.10.2004, p. 1670-1673.

Research output: Contribution to journalArticle

@article{2413241e9f4749209af9748714a0c5de,
title = "Pentoxifylline inhibits tumor necrosis factor-alpha induced synthesis of complement component C3 in human endothelial cells",
abstract = "Vascular endothelium is a major target for the inflammatory damage that occurs with multiple organ dysfunction associated with sepsis and other trauma. The growing appreciation of endothelium as a target of inflammation has obscured the importance of these cells as a source of inflammatory mediators. In the following study we evaluated the ability of tumor necrosis factor-alpha (TNF) to induce the synthesis of complement component C3 in human umbilical vein endothelial cells (HUVEC) and whether pentoxifylline (PTX) could reduce C3 expression. Confluent monolayers of HUVEC were treated with increasing concentrations of TNF with and without two concentrations of PTX. Concentrations of C3 were determined every 48 h for 144 h in cellular supernatants and C3 mRNA was amplified using RT-PCR. TNF increased C3 release from HUVEC in a concentration dependent manner. PTX added at the same time as TNF significantly reduced C3 release at the 96 h time point. Consistent with data on C3 release PTX inhibited the increased C3 mRNA expression associated with TNF treatment. TNF increases C3 synthesis and release from endothelial cells which were inhibited by clinical concentrations of PTX. This data further supports the potential benefit of PTX in multiple organ dysfunction and other inflammatory processes involving the endothelium by inhibiting one of the major mediators of vascular damage.",
keywords = "C3, Complement, Human umbilical vein endothelial cell (HUVEC), Pentoxifylline, Tumor necrosis factor (TNF)-α",
author = "Hoie, {Eric Brian} and McGuire, {Timothy R} and Leuschen, {Patricia Mary} and Zach, {Terrence Leo}",
year = "2004",
month = "10",
day = "1",
doi = "10.1248/bpb.27.1670",
language = "English (US)",
volume = "27",
pages = "1670--1673",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "10",

}

TY - JOUR

T1 - Pentoxifylline inhibits tumor necrosis factor-alpha induced synthesis of complement component C3 in human endothelial cells

AU - Hoie, Eric Brian

AU - McGuire, Timothy R

AU - Leuschen, Patricia Mary

AU - Zach, Terrence Leo

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Vascular endothelium is a major target for the inflammatory damage that occurs with multiple organ dysfunction associated with sepsis and other trauma. The growing appreciation of endothelium as a target of inflammation has obscured the importance of these cells as a source of inflammatory mediators. In the following study we evaluated the ability of tumor necrosis factor-alpha (TNF) to induce the synthesis of complement component C3 in human umbilical vein endothelial cells (HUVEC) and whether pentoxifylline (PTX) could reduce C3 expression. Confluent monolayers of HUVEC were treated with increasing concentrations of TNF with and without two concentrations of PTX. Concentrations of C3 were determined every 48 h for 144 h in cellular supernatants and C3 mRNA was amplified using RT-PCR. TNF increased C3 release from HUVEC in a concentration dependent manner. PTX added at the same time as TNF significantly reduced C3 release at the 96 h time point. Consistent with data on C3 release PTX inhibited the increased C3 mRNA expression associated with TNF treatment. TNF increases C3 synthesis and release from endothelial cells which were inhibited by clinical concentrations of PTX. This data further supports the potential benefit of PTX in multiple organ dysfunction and other inflammatory processes involving the endothelium by inhibiting one of the major mediators of vascular damage.

AB - Vascular endothelium is a major target for the inflammatory damage that occurs with multiple organ dysfunction associated with sepsis and other trauma. The growing appreciation of endothelium as a target of inflammation has obscured the importance of these cells as a source of inflammatory mediators. In the following study we evaluated the ability of tumor necrosis factor-alpha (TNF) to induce the synthesis of complement component C3 in human umbilical vein endothelial cells (HUVEC) and whether pentoxifylline (PTX) could reduce C3 expression. Confluent monolayers of HUVEC were treated with increasing concentrations of TNF with and without two concentrations of PTX. Concentrations of C3 were determined every 48 h for 144 h in cellular supernatants and C3 mRNA was amplified using RT-PCR. TNF increased C3 release from HUVEC in a concentration dependent manner. PTX added at the same time as TNF significantly reduced C3 release at the 96 h time point. Consistent with data on C3 release PTX inhibited the increased C3 mRNA expression associated with TNF treatment. TNF increases C3 synthesis and release from endothelial cells which were inhibited by clinical concentrations of PTX. This data further supports the potential benefit of PTX in multiple organ dysfunction and other inflammatory processes involving the endothelium by inhibiting one of the major mediators of vascular damage.

KW - C3

KW - Complement

KW - Human umbilical vein endothelial cell (HUVEC)

KW - Pentoxifylline

KW - Tumor necrosis factor (TNF)-α

UR - http://www.scopus.com/inward/record.url?scp=21644466980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21644466980&partnerID=8YFLogxK

U2 - 10.1248/bpb.27.1670

DO - 10.1248/bpb.27.1670

M3 - Article

VL - 27

SP - 1670

EP - 1673

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 10

ER -